|
1.
|
|
10 p, 673.5 KB |
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors : A Retrospective, Multinational, Multicentre Study
/
Torres, Tiago (University of Porto, Portugal) ;
Chiricozzi, Andrea (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Lé, Ana Maria (Centro Académico Clínico ICBAS - CHP, Porto, Portugal) ;
Marzano, Angelo Valerio (Università degli Studi di Milano, Italy) ;
Dapavo, Paolo (University of Turin, Italy) ;
Dauden, Esteban (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid) ;
Carrascosa, Jόse-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Duarte, Gleison (Instituto Bahiano de Imunoterapias-IBIS, Salvador, Brazil) ;
Carvalho, André V. E. (Hospital Moinhos de Vento, Porto Alegre, Brazil) ;
Romiti, Ricardo (University of São Paulo, Brazil) ;
Rompoti, Natalia (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Teixeira, Laetitia (Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal) ;
Abreu, Miguel (University of Porto, Portugal) ;
Ippoliti, Elena (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Maronese, Carlo Alberto (Università degli Studi di Milano, Italy) ;
Llamas-Velasco, Mar (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP)) ;
Vilarrasa-Rull, Eva (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
del Alcázar, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Daponte, Athina-Ioanna (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Papoutsaki, Marina (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Carugno, Andrea (ASST Papa Giovanni XXIII, Bergamo, Italy) ;
Bellinato, Francesco (University Hospital of Verona, Italy) ;
Gisondi, Paolo (University Hospital of Verona, Italy) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. [...]
2024 -  10.1007/s40257-024-00845-4
American Journal of Clinical Dermatology, Vol. 25, Num. 2 (march 2024) , p. 333-342
|
|
|
2.
|
|
2 p, 292.1 KB |
Corrigendum : The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published. [...]
2023 - 10.3389/fimmu.2023.1332177
Frontiers in immunology, Vol. 14 (2023) , p. 1332177
|
|
|
3.
|
|
14 p, 4.2 MB |
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
/
Navarro-Compán, Victoria (Hospital Universitario La Paz (Madrid)) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Fernández-Carballido, Cristina (Hospital Universitario San Juan de Alicante) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Pinto, José Antonio (Complejo Hospitalario Universitario de A Coruña) ;
Galíndez-Aguirregoikoa, Eva (Hospital Universitario de Basurto) ;
Zarco, Pedro (Hospital Universitario Fundación Alcorcón) ;
Joven, Beatriz (Hospital 12 de Octubre (Madrid)) ;
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Arias-Santiago, Salvador (Universidad de Granada) ;
Sanz Sanz, Jesús (Hospital Universitario Puerta del Hierro Majadahonda) ;
Queiro, Ruben (Hospital Universitario Central de Asturias) ;
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-κB) pathway. [...]
2023 - 10.3389/fimmu.2023.1191782
Frontiers in immunology, Vol. 14 (august 2023)
|
|
|
4.
|
|
|
5.
|
|
10 p, 2.1 MB |
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks : A retrospective, observational, multicentre study by the Spanish Psoriasis Group
/
del Alcázar Viladomiu, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
López-Ferrer, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez-Doménech, Álvaro (Hospital General Universitario de Valencia) ;
Ruíz Villaverde, Ricardo (Hospital Clínico San Cecilio) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Rocamora, V. (Hospital de Manacor) ;
Julià, M. (Hospital de Basurto (Bilbao, Biscaia)) ;
Notario, J. (Hospital Universitari de Bellvitge) ;
Fernández-Freire, L. R. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sahuquillo-Torralba, A. (Hospital Universitari i Politècnic La Fe (València)) ;
Vidal, D. (Hospital de Sant Joan Despí Moisès Broggi) ;
Rivera, Raquel (Hospital Universitario 12 de Octubre (Madrid)) ;
Carretero, G. (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Mateu, A. (Hospital Universitari Doctor Peset (València)) ;
De la Cueva, Pablo (Hospital Universitario Infanta Leonor) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. [...]
2021 - 10.1111/dth.15231
Dermatologic therapy, 2021
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
